About Mithril Medicine
Mithril Medicine is a biotechnology company that develops bispecific "bridging" antibodies for two rare, severe forms of muscular dystrophy: LAMA2-related congenital muscular dystrophy (LAMA2-CMD) and alpha-dystroglycanopathy. It ran as a "pipeline-in-a-person". Its founder was the only full-time employee and used Claude to coordinate contracts, logistics and experiments across 11 outside laboratories, with support from part-time scientific consultants. In under 18 months it took an antibody therapy for LAMA2-CMD from idea to positive preclinical mouse studies. Mice on the highest dose showed roughly double the grip and muscle strength of untreated mice, but no human trials have started yet. Its intended beneficiaries are children with these rare diseases, and its research has been carried out through contract labs in the United States. The company is headquartered in Cambridge, Massachusetts, United States.